Our top pick for
Avidity Biosciences, Inc is a biotechnology business based in the US. Avidity Biosciences shares (RNA) are listed on the NASDAQ and all prices are listed in US Dollars.
|Latest market close||USD$33.32|
|52-week range||USD$23.06 - USD$37.46|
|50-day moving average||USD$28.4546|
|200-day moving average||USD$28.7666|
|Wall St. target price||USD$43.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||31.60%|
|1 month (2020-12-15)||3.09%|
|3 months (2020-10-15)||19.77%|
|6 months (2020-07-15)||26.40%|
|1 year (2020-01-13)||N/A|
|2 years (2019-01-13)||N/A|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-13)||N/A|
|Revenue TTM||USD$6.1 million|
|Gross profit TTM||USD$-12,220,000|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$1.1 billion|
TTM: trailing 12 months
There are currently 1.6 million Avidity Biosciences shares held short by investors – that's known as Avidity Biosciences's "short interest". This figure is 10.9% up from 1.4 million last month.
There are a few different ways that this level of interest in shorting Avidity Biosciences shares can be evaluated.
Avidity Biosciences's "short interest ratio" (SIR) is the quantity of Avidity Biosciences shares currently shorted divided by the average quantity of Avidity Biosciences shares traded daily (recently around 133094.38390612). Avidity Biosciences's SIR currently stands at 11.93. In other words for every 100,000 Avidity Biosciences shares traded daily on the market, roughly 11930 shares are currently held short.
However Avidity Biosciences's short interest can also be evaluated against the total number of Avidity Biosciences shares, or, against the total number of tradable Avidity Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Avidity Biosciences's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Avidity Biosciences shares in existence, roughly 40 shares are currently held short) or 0.0508% of the tradable shares (for every 100,000 tradable Avidity Biosciences shares, roughly 51 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Avidity Biosciences.
Find out more about how you can short Avidity Biosciences stock.
We're not expecting Avidity Biosciences to pay a dividend over the next 12 months.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of muscle atrophy, duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe diseases. Avidity Biosciences, Inc. was founded in 2012 and is based in La Jolla, California.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.